Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Investor Update - December 4, 2023 Category: Pharmaceuticals Source Type: news

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Media News - December 4, 2023 Category: Pharmaceuticals Source Type: news

FDA Approves Zepbound, the Most Potent Weight Loss Drug Yet
Weight loss drugs have dominated the headlines over the past year, and now there’s a new medication that may be the most effective one yet. On Nov. 11, the U.S. Food and Drug Administration (FDA) approved tirzepatide (which will be sold under the brand name Zepbound), to treat overweight and obesity. Made by Eli Lilly and Co., the drug is already approved, in different doses, for type 2 diabetes, as Mounjaro, and its effectiveness in those patients is due in part to its weight loss effects. [time-brightcove not-tgx=”true”] About 70% of Americans are overweight, with a body mass index (BMI) between ...
Source: TIME: Health - November 9, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news

Sodium-glucose cotransporter 2 inhibitors vs incretin-based drugs and risk of fractures for type 2 diabetes - Ko HY, Bea S, Jeong HE, Park S, Cho YM, Kong SH, Shin JY.
IMPORTANCE: Postmenopausal individuals with type 2 diabetes are susceptible to fractures due to the interaction of elevated blood glucose levels and a deficiency of the hormone estrogen. Despite continued concerns of fracture risks associated with sodium-g... (Source: SafetyLit)
Source: SafetyLit - October 2, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Postmenopausal Fracture Risk for SGLT2 Inhibitors Similar to Other Diabetes Drugs
(MedPage Today) -- SGLT2 inhibitors were associated with a lower or similar fracture risk compared with incretin-based antidiabetic agents in postmenopausal women with type 2 diabetes, according to a claims-based study involving two independent... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 26, 2023 Category: Cardiology Source Type: news

New Uses Emerge for Obesity and Diabetes Drugs New Uses Emerge for Obesity and Diabetes Drugs
Experts weigh in on recent developments in incretin drug therapy that have ' changed completely ' the prospects for treating both conditions.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 1, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes
The U.S. Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 11, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Semaglutide Use Surges in US Adults With Diabetes Semaglutide Use Surges in US Adults With Diabetes
By the first quarter 2022, 57% of US adults with type 2 diabetes taking an incretin-based agent were taking a GLP-1 receptor agonist; DPP-4 inhibitor use fell to 39% of these scripts.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 28, 2023 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

New T2D Medications and Technology Offer'Bespoke' Approach New T2D Medications and Technology Offer'Bespoke' Approach
Akshay Jain, MD, and Kevin Fernando, MSc, discuss highlights regarding incretin therapies and new technology for type 2 diabetes from the 83rd Annual ADA Scientific Sessions.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 18, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news

Obesity Takes Center Stage at Slimmed-Down Diabetes Meeting Obesity Takes Center Stage at Slimmed-Down Diabetes Meeting
The American Diabetes Association Scientific Sessions will feature results from multiple incretin drug trials, data on bariatric surgery versus lifestyle management, new interactive debates, and much more.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 20, 2023 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news

New Incretin Co-agonists Could Change Obesity Therapy New Incretin Co-agonists Could Change Obesity Therapy
New pharmaceutical treatments are coming closer to matching the hormonal changes achieved through surgical treatment of obesity.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

' Twincretin' Tirzepatide Gets FDA Approval for Type 2 Diabetes'Twincretin' Tirzepatide Gets FDA Approval for Type 2 Diabetes
Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also express concern about cost and patient accessibility.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 14, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

Tirzepatide (Mounjaro) Gets FDA Approval for Type 2 Diabetes Tirzepatide (Mounjaro) Gets FDA Approval for Type 2 Diabetes
Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also express concern about cost and patient accessibility.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 13, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

The Effect of Melatonin on Incretin Hormones The Effect of Melatonin on Incretin Hormones
In what ways does melatonin impact incretin hormones, and what are the implications?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Join the International Society of Endocrinology ’s expert webinar
Society for Endocrinology members are also members of the International Society of Endocrinology (ISE).Register to join the ISE webinar taking place on Tuesday 26 January, at 4:00 - 5:30 PM CET, to take part in an interactive discussion with top experts. The webinar will explore the role of GLP-1 RAs in the current landscape of incretin therapies for type 2 diabetes. After the session, you will be invited to solve a CME-accredited case study on the ISE Global Education Hub, to apply what you learned. The webinar will consist of the following interactive parts:• Part 1: Have diabetes goals changed...
Source: Society for Endocrinology - January 19, 2021 Category: Endocrinology Source Type: news